Can a wearable glucose sensor be trusted in the ICU? new study aims to find out

NCT ID NCT07611721

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is checking how accurate the Dexcom G7 continuous glucose monitor is for patients in the intensive care unit after major abdominal surgery or organ transplant. Researchers will place two sensors on each patient—one that is calibrated and used to guide insulin dosing, and one that is not calibrated and kept hidden. By comparing the readings from both sensors to standard blood glucose measurements, they hope to determine whether the device can reliably detect dangerous highs and lows in blood sugar in critically ill patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Dexcom G7 continuous glucose monitor (device)

What this could lead to

If successful, this could show that the Dexcom G7 is reliable enough for routine use in intensive care, potentially improving glucose management for critically ill patients.

What could go wrong

This is a small, early-stage accuracy study (62 participants) in a specific ICU setting, so results may not apply to all patients or general hospital wards. The device may still have errors in detecting very low or high blood sugar.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTENSIVE CARE (ICU) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital primary megaureter diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Institute of Clinical and Experimental Medice

    RECRUITING

    Prague, Czechia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••